Overall Trading Platform
Moderna, Inc is a biotechnology business based in the US. Moderna shares (MRNA) are listed on the NASDAQ and all prices are listed in US Dollars. Moderna employs 1,300 staff and has a trailing 12-month revenue of around USD$2.7 billion.
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
Since the stock market crash in March caused by coronavirus, Moderna's share price has had significant positive movement.
Its last market close was USD$148.38, which is 87.71% up on its pre-crash value of USD$18.23 and 728.48% up on the lowest point reached during the March crash when the shares fell as low as USD$17.91.
If you had bought USD$1,000 worth of Moderna shares at the start of February 2020, those shares would have been worth USD$1,303.79 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$7,281.01.
|Latest market close||USD$148.38|
|52-week range||USD$46.13 - USD$189.26|
|50-day moving average||USD$155.4257|
|200-day moving average||USD$137.2891|
|Wall St. target price||USD$179.25|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$1.492|
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-05-07)||N/A|
|1 month (2021-04-16)||-13.13%|
|3 months (2021-02-18)||-12.50%|
|6 months (2020-11-17)||59.29%|
|1 year (2020-05-15)||122.49%|
|2 years (2019-05-17)||542.89%|
|3 years (2018-05-14)||N/A|
|5 years (2016-05-14)||N/A|
Valuing Moderna stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Moderna's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Moderna's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 108x. In other words, Moderna shares trade at around 108x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Moderna's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$673.1 million.
The EBITDA is a measure of a Moderna's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$2.7 billion|
|Operating margin TTM||23.2%|
|Gross profit TTM||USD$-574,877,000|
|Return on assets TTM||5.37%|
|Return on equity TTM||21.83%|
|Market capitalisation||USD$64.8 billion|
TTM: trailing 12 months
There are currently 12.9 million Moderna shares held short by investors – that's known as Moderna's "short interest". This figure is 9.2% up from 11.8 million last month.
There are a few different ways that this level of interest in shorting Moderna shares can be evaluated.
Moderna's "short interest ratio" (SIR) is the quantity of Moderna shares currently shorted divided by the average quantity of Moderna shares traded daily (recently around 10.0 million). Moderna's SIR currently stands at 1.3. In other words for every 100,000 Moderna shares traded daily on the market, roughly 1300 shares are currently held short.
However Moderna's short interest can also be evaluated against the total number of Moderna shares, or, against the total number of tradable Moderna shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Moderna's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Moderna shares in existence, roughly 30 shares are currently held short) or 0.0441% of the tradable shares (for every 100,000 tradable Moderna shares, roughly 44 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Moderna.
Robinhood is expected to go public, here’s what you need to know if you’re looking to buy in from Singapore.
Steps to owning and managing Roblox stocks, with 24-hour and historical pricing before you buy.
Steps to owning and managing Coinbase shares.
Ever wondered how to buy shares in Blue Apron? We explain how and compare a range of providers that can give you access to many brands, including Blue Apron.
Ever wondered how to buy shares in B&G Foods? We explain how and compare a range of providers that can give you access to many brands, including B&G Foods.
Ever wondered how to buy shares in Kandi? We explain how and compare a range of providers that can give you access to many brands, including Kandi.
Ever wondered how to buy shares in Ayro? We explain how and compare a range of providers that can give you access to many brands, including Ayro.
Ever wondered how to buy shares in The Children’s Place? We explain how and compare a range of providers that can give you access to many brands, including The Children’s Place.
Ever wondered how to buy shares in Tanger Factory Outlet Centers? We explain how and compare a range of providers that can give you access to many brands, including Tanger Factory Outlet Centers.
Ever wondered how to buy shares in Blockbuster? We explain how and compare a range of providers that can give you access to many brands, including Blockbuster.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.